Michael A. Insko, M.S.

Founded by Michael A. Insko, M.S., Insko Insights combines more than two decades of experience spanning discovery research, nonclinical development, toxicology, pharmacokinetics, and laboratory operations across biotechnology and pharmaceutical organizations.

Throughout his career, Michael has worked with organizations ranging from early-stage biotechnology companies to publicly traded pharmaceutical organizations, including: Gensia Pharmaceuticals, Ambit Biosciences, Metabasis Therapeutics, Ikaria Research, Oncothyreon, and Faraday Pharmaceuticals, Inc.

He has helped advance therapeutic programs through critical development milestones with experience including designing and overseeing nonclinical studies, managing complex CRO relationships, authoring regulatory documentation, developing scientific communication strategies, and partnering with clinicians, investigators, and industry leaders.

Key career contributions included advancing FDY-5301 from discovery all the way through Phase III clinical trials at Faraday Pharmaceuticals, Inc, supporting the development tucatinib (TUKYSA®) while at Oncothyreon, and pioneering technologies that remain widely used in kinase drug discovery and translational pharmacology today such as KinomeScan™ developed at Ambit Biosciences.

His experience spans the full continuum from early-stage research through commercialization readiness, effectively bridging scientific, clinical, and business objectives to advance innovative therapies and improve patient outcomes.